liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Ramiprilate Inhibits Functional Matrix Metalloproteinase Activity in Crohns Disease Fistulas
Department of Gastroenterology, Herlev Hospital, University of Copenhagen, Herlev, Denmark.
Östergötlands Läns Landsting, Local Health Care Services in Central Östergötland, Department of Acute Health Care.
Department of Pathology, Herlev Hospital, University of Copenhagen, Herlev, Denmark.
Department of Gastroenterology, Herlev Hospital, University of Copenhagen, Herlev, Denmark.
Show others and affiliations
2011 (English)In: Basic & Clinical Pharmacology & Toxicology, ISSN 1742-7835, E-ISSN 1742-7843, Vol. 109, no 3, 208-216 p.Article in journal (Refereed) Published
Abstract [en]

Increased expression of matrix metalloproteinase (MMP)-2, -3 and -9 has been demonstrated in Crohns disease fistulas, but it is unknown whether these enzymes are biologically active and represent a therapeutic target. Therefore, we investigated the proteolytic activity of MMPs in fistula tissue and examined the effect of inhibitors, including clinically available drugs that beside their main action also suppress MMPs. Fistula specimens were obtained by surgical excision from 22 patients with Crohns disease and from 10 patients with fistulas resulting from other causes. Colonic endoscopic biopsies from six controls were also included. Total functional MMP activity was measured by a high-pressure liquid chromatography (HPLC)-based, fluorogenic MMP-substrate cleavage assay, and the specific activity of MMP-2, -3 and -9 by the MMP Biotrak Activity Assay. The MMP inhibitors comprised ethylene-diamine-tetraacetic acid (EDTA), the synthetic broad-spectrum inhibitor, GM6001, the angiotensin-converting enzyme (ACE) inhibitor, ramiprilate, and the tetracycline, doxycycline. In Crohns disease fistulas, about 50% of the total protease activity was attributable to MMP activity. The average total MMP activity was significantly higher (about 3.5-times) in Crohns fistulas (471 FU/mu g protein, range 49-2661) compared with non-Crohns fistulas [134 FU/mu g protein, range 0-495, (p andlt; 0.05)] and normal colon [153 FU/mu g protein, range 77-243, (p andlt; 0.01)]. MMP-3 activity was increased in Crohns fistulas (1.4 ng/ml, range 0-9.83) compared with non-Crohns fistulas, [0.32 ng/ml, range 0-2.66, (p andlt; 0.02)]. The same applied to MMP-9 activity [0.64 ng/ml, range 0-5.66 and 0.17 ng/ml, range 0-1.1, respectively (p andlt; 0.04)]. Ramiprilate significantly decreased the average total MMP activity level by 42% and suppressed the specific MMP-3 activity by 72%, which is comparable to the effect of GM6001 (87%). Moreover, MMP-9 activity was completely blunted by ramiprilate. Doxycycline had no effect on MMP activity. Increased functional MMP activity, notably MMP-3 and -9, is present in Crohns fistulas and may be inhibited by ramiprilate, a widely available ACE inhibitor.

Place, publisher, year, edition, pages
WILEY-BLACKWELL, COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA , 2011. Vol. 109, no 3, 208-216 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-70320DOI: 10.1111/j.1742-7843.2011.00713.xISI: 000293795300008OAI: diva2:438358
Available from: 2011-09-02 Created: 2011-09-02 Last updated: 2011-09-06

Open Access in DiVA

No full text

Other links

Publisher's full text
By organisation
Department of Acute Health Care
In the same journal
Basic & Clinical Pharmacology & Toxicology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 27 hits
ReferencesLink to record
Permanent link

Direct link